118 related articles for article (PubMed ID: 38586956)
1. Factors affecting timing of hypothyroidism following radioactive iodine therapy (RAIT) for patients with Graves' disease: A 12-month observational study.
Mahmoud HA; Alsanory AAAA; Mostafa HG; Hassan ER
Nucl Med Commun; 2024 Jun; 45(6):499-509. PubMed ID: 38586956
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
Kaplowitz PB; Jiang J; Vaidyanathan P
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.
Hu RT; Liu DS; Li B
BMC Endocr Disord; 2020 May; 20(1):76. PubMed ID: 32471411
[TBL] [Abstract][Full Text] [Related]
5. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
6. TPO antibody status prior to first radioactive iodine therapy as a predictive parameter for hypothyroidism in Graves' disease.
Verdickt S; Van Nes F; Moyson C; Maes T; Van Crombrugge P; Van den Bruel A; Decallonne B
Eur Thyroid J; 2022 Aug; 11(4):. PubMed ID: 35687484
[TBL] [Abstract][Full Text] [Related]
7. Radioactive Iodine Therapy of Graves' Disease in Patients Pretreated With Methimazole Without Radioiodine Uptake for Dose Estimation.
Mihailescu DV; Hoscheit C; Fogelfeld L
Endocr Pract; 2024 Apr; 30(4):333-339. PubMed ID: 38307459
[TBL] [Abstract][Full Text] [Related]
8. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease.
Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM
J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034
[TBL] [Abstract][Full Text] [Related]
9. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease.
Martin NM; Patel M; Nijher GM; Misra S; Murphy E; Meeran K
Clin Endocrinol (Oxf); 2012 Oct; 77(4):621-7. PubMed ID: 22443227
[TBL] [Abstract][Full Text] [Related]
11. Thyroid volume is the key predictor of hyperthyroidism remission after radioactive iodine therapy in pediatric patients.
Sheremeta M; Korchagina M; Trukhin A; Nagaeva E; Bezlepkina O; Peterkova V
Eur J Pediatr; 2023 Nov; 182(11):4931-4937. PubMed ID: 37606704
[TBL] [Abstract][Full Text] [Related]
12. Pattern of presentation of Graves' disease and response to radioiodine therapy in South African men.
Onimode YA; Dairo DM; Ellmann A
Pan Afr Med J; 2018; 29():48. PubMed ID: 29875930
[TBL] [Abstract][Full Text] [Related]
13. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
14. Transient Hypothyroidism after Radioiodine for Graves' Disease: Challenges in Interpreting Thyroid Function Tests.
Sheehan MT; Doi SA
Clin Med Res; 2016 Mar; 14(1):40-5. PubMed ID: 26864507
[TBL] [Abstract][Full Text] [Related]
15. The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level.
Adamali HI; Gibney J; O'Shea D; Casey M; McKenna TJ
Ir J Med Sci; 2007 Sep; 176(3):199-203. PubMed ID: 17632747
[TBL] [Abstract][Full Text] [Related]
16. Influence of high tissue-absorbed dose on anti-thyroid antibodies in radioiodine therapy of Graves' disease patients.
Listewnik MH; Piwowarska-Bilska H; Jasiakiewicz K; Birkenfeld B
Adv Clin Exp Med; 2021 Sep; 30(9):913-921. PubMed ID: 34418335
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Prolonged Euthyroidism After Radioactive Iodine Treatment for Graves' Disease: A Pilot Study.
Lu JY; Chen KH; Shih SR; Wen FY; Wu WC; Chen TC; Hu FC
Endocr Pract; 2023 Feb; 29(2):89-96. PubMed ID: 36396015
[TBL] [Abstract][Full Text] [Related]
18. What influences early hypothyroidism after radioiodine treatment for Graves' hyperthyroidism?
Vijayakumar V; Ali S; Nishino T; Nusynowitz M
Clin Nucl Med; 2006 Nov; 31(11):688-9. PubMed ID: 17053385
[TBL] [Abstract][Full Text] [Related]
19. Prospective study to evaluate radioactive iodine of 20 mCi vs 10-15 mCi in Graves' disease.
Kanokwongnuwat W; Penpong N
BMC Endocr Disord; 2024 Apr; 24(1):54. PubMed ID: 38664774
[TBL] [Abstract][Full Text] [Related]
20. Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves' disease.
Ze Y; Shao F; Feng X; Shen S; Bi Y; Zhu D; Zhang X
BMC Endocr Disord; 2022 Dec; 22(1):319. PubMed ID: 36522617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
